期刊
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
卷 157, 期 -, 页码 -出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2020.103194
关键词
Lung cancer; Mutations; Gene rearrangements; Predictive markers; Therapy; PCR; NGS; Review
资金
- Russian Science Foundation [17-75-30027]
- Russian Science Foundation [17-75-30027] Funding Source: Russian Science Foundation
Molecular testing is essential in NSCLC management, including detecting mutations and translocations, as well as analyzing protein expression. Efforts are ongoing to integrate multiple molecular assays into a single diagnostic pipeline for NSCLC.
Molecular testing has become a mandatory component of the non-small cell lung cancer (NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the analysis of ALK, ROS1, RET and NTRK trans locations have already been incorporated in the NSCLC diagnostic standards, and the inhibitors of these kinases are in routine clinical use. There are emerging biomarkers, e.g., KRAS G12C substitutions and HER2 activating alterations, which are likely to enter NSCLC guidelines upon the approval of the corresponding drugs. In addition to genetic examination, NSCLCs are usually subjected to the analysis of PD-L1 protein expression in order to direct the use of immune checkpoint inhibitors. Comprehensive NSCLC testing for multiple predictive markers requires the analysis of distinct biological molecules (DNA, RNA, proteins) and, therefore, the involvement of different analytical platforms (PCR, DNA sequencing, immunohistochemistry, FISH). There are ongoing efforts aimed at the integration of multiple NSCLC molecular assays into a single diagnostic pipeline.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据